{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:13:23Z","timestamp":1790867603071,"version":"4.1.0"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","award":["YTCR 05\/21"],"award-info":[{"award-number":["YTCR 05\/21"]}],"id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PCEFP3_194609"],"award-info":[{"award-number":["PCEFP3_194609"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008486","name":"Schweizerische Multiple Sklerose Gesellschaft","doi-asserted-by":"publisher","award":["(FG-1708-28871"],"award-info":[{"award-number":["(FG-1708-28871"]}],"id":[{"id":"10.13039\/501100008486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016071","name":"Margot und Erich Goldschmidt und Peter Ren\u00e9 Jacobson-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Propatient-Stiftung Universit\u00e4tsspital Basel"},{"DOI":"10.13039\/501100023177","name":"Fondation Pierre Mercier pour la Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023177","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016015","name":"University Hospital Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40265-022-01826-9","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T05:02:31Z","timestamp":1674622951000},"page":"135-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-5484","authenticated-orcid":false,"given":"Julia","family":"Flammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-604X","authenticated-orcid":false,"given":"Tradite","family":"Neziraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-622X","authenticated-orcid":false,"given":"Stephan","family":"R\u00fcegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-1872","authenticated-orcid":false,"given":"Anne-Katrin","family":"Pr\u00f6bstel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"9971","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","volume":"385","author":"SL Mosh\u00e9","year":"2015","unstructured":"Mosh\u00e9 SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884\u201398.","journal-title":"Lancet"},{"issue":"10172","key":"1826_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume":"393","author":"RD Thijs","year":"2019","unstructured":"Thijs RD, Surges R, O\u2019Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689\u2013701.","journal-title":"Lancet"},{"issue":"2","key":"1826_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","volume":"54","author":"E Beghi","year":"2020","unstructured":"Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185\u201391.","journal-title":"Neuroepidemiology"},{"issue":"11","key":"1826_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaneurol.2021.3113","volume":"78","author":"C Steriade","year":"2021","unstructured":"Steriade C, Gillinder L, Rickett K, Hartel G, Higdon L, Britton J, et al. Discerning the role of autoimmunity and autoantibodies in epilepsy: a review. JAMA Neurol. 2021;78(11):1383\u201390.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","volume":"74","author":"D Dubey","year":"2017","unstructured":"Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K, et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. 2017;74(4):397\u2013402.","journal-title":"JAMA Neurol"},{"key":"1826_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2018.09.009","volume":"63","author":"M Elisak","year":"2018","unstructured":"Elisak M, Krysl D, Hanzalova J, Volna K, Bien CG, Leypoldt F, et al. The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients. Seizure. 2018;63:1\u20136.","journal-title":"Seizure"},{"issue":"9","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/epi.14534","volume":"59","author":"AW N\u00f3brega-Jr","year":"2018","unstructured":"N\u00f3brega-Jr AW, Gregory CP, Schlindwein-Zanini R, Neves FS, Wolf P, Walz R, et al. Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies. Epilepsia. 2018;59(9):e152\u20136.","journal-title":"Epilepsia"},{"issue":"4","key":"1826_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ana.26013","volume":"89","author":"M de Bruijn","year":"2021","unstructured":"de Bruijn M, Bastiaansen AEM, Mojzisova H, van Sonderen A, Thijs RD, Majoie MJM, et al. Antibodies contributing to focal epilepsy signs and symptoms score. Ann Neurol. 2021;89(4):698\u2013710.","journal-title":"Ann Neurol"},{"issue":"1","key":"1826_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2016.12.1.1","volume":"12","author":"E Lancaster","year":"2016","unstructured":"Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol (Seoul, Korea). 2016;12(1):1\u201313.","journal-title":"J Clin Neurol (Seoul, Korea)."},{"issue":"3","key":"1826_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/JCI125178","volume":"129","author":"C Geis","year":"2019","unstructured":"Geis C, Planagum\u00e0 J, Carre\u00f1o M, Graus F, Dalmau J. Autoimmune seizures and epilepsy. J Clin Invest. 2019;129(3):926\u201340.","journal-title":"J Clin Invest"},{"issue":"2","key":"1826_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1152\/physrev.00010.2016","volume":"97","author":"J Dalmau","year":"2017","unstructured":"Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839\u201387.","journal-title":"Physiol Rev"},{"issue":"4","key":"1826_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671\u20135.","journal-title":"Epilepsia"},{"issue":"7","key":"1826_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/epi.16571","volume":"61","author":"C Steriade","year":"2020","unstructured":"Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia. 2020;61(7):1341\u201351.","journal-title":"Epilepsia"},{"issue":"7","key":"1826_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757\u201368.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1826_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391\u2013404.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1826_CR16","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","volume":"46","author":"RS Fisher","year":"2005","unstructured":"Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470\u20132.","journal-title":"Epilepsia"},{"issue":"3","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","volume":"30","author":"M Spatola","year":"2017","unstructured":"Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol. 2017;30(3):345\u201353.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"1826_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/epi.16807","volume":"62","author":"AK Yeshokumar","year":"2021","unstructured":"Yeshokumar AK, Coughlin A, Fastman J, Psaila K, Harmon M, Randell T, et al. Seizures in autoimmune encephalitis-A systematic review and quantitative synthesis. Epilepsia. 2021;62(2):397\u2013407.","journal-title":"Epilepsia"},{"key":"1826_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.seizure.2021.02.010","volume":"86","author":"M Ilyas-Feldmann","year":"2021","unstructured":"Ilyas-Feldmann M, Pr\u00fc\u00df H, Holtkamp M. Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis. Seizure. 2021;86:138\u201343.","journal-title":"Seizure."},{"issue":"4","key":"1826_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia"},{"issue":"3","key":"1826_CR21","first-page":"513","volume":"63","author":"SJ R\u00fcegg","year":"1988","unstructured":"R\u00fcegg SJ, Jungi TW. Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells. Immunology. 1988;63(3):513\u201320.","journal-title":"Immunology"},{"issue":"1","key":"1826_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","volume":"112","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006;112(1):57\u201370.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1826_CR23","first-page":"153","volume":"15","author":"P Ehling","year":"2015","unstructured":"Ehling P, Melzer N, Budde T, Meuth SG. CD8+ T cell-mediated neuronal dysfunction and degeneration in limbic encephalitis. Front Neurol. 2015;15(6):153.","journal-title":"Front Neurol"},{"issue":"12","key":"1826_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","volume":"10","author":"J Granerod","year":"2010","unstructured":"Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835\u201344.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1826_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00415-009-5431-9","volume":"257","author":"F Graus","year":"2010","unstructured":"Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010;257(4):509\u201317.","journal-title":"J Neurol"},{"key":"1826_CR26","doi-asserted-by":"crossref","unstructured":"Newman M, Airey C, Blum S, Scott JG, Wong RC, Gillis D. Chapter 9\u2014autoimmune encephalitis: clinical features, pathophysiology, and management. In: Minagar A, editor. Neuroinflammation (Second Edition): Academic Press; 2018. pp. 193-216.","DOI":"10.1016\/B978-0-12-811709-5.00010-7"},{"issue":"3","key":"1826_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1212\/CPJ.0b013e31826af23e","volume":"2","author":"MR Rosenfeld","year":"2012","unstructured":"Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis: five new things. Neurol Clin Pract. 2012;2(3):215\u201323.","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"1826_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","volume":"1413","author":"MG Huijbers","year":"2018","unstructured":"Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci. 2018;1413(1):92\u2013103.","journal-title":"Ann N Y Acad Sci"},{"key":"1826_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117420","volume":"424","author":"G Saitakis","year":"2021","unstructured":"Saitakis G, Chwalisz BK. The neurology of IGG4-related disease. J Neurol Sci. 2021;424: 117420.","journal-title":"J Neurol Sci"},{"key":"1826_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3389\/fneur.2019.00804","volume":"10","author":"T Blinder","year":"2019","unstructured":"Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol. 2019;10:804.","journal-title":"Front Neurol"},{"issue":"5","key":"1826_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen A, Ari\u00f1o H, Petit-Pedrol M, Leypoldt F, K\u00f6rtv\u00e9lyessy P, Wandinger K-P, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521\u20138.","journal-title":"Neurology"},{"issue":"11","key":"1826_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16(11):601\u201317.","journal-title":"Nat Rev Neurol"},{"issue":"17","key":"1826_CR33","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","volume":"30","author":"EG Hughes","year":"2010","unstructured":"Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866\u201375.","journal-title":"J Neurosci"},{"issue":"6","key":"1826_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000161","volume":"2","author":"EP Flanagan","year":"2015","unstructured":"Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm. 2015;2(6): e161.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"11","key":"1826_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/jnnp-2017-317780","volume":"89","author":"J Heine","year":"2018","unstructured":"Heine J, Pr\u00fcss H, Kopp UA, Wegner F, Then Bergh F, M\u00fcnte T, et al. Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis. J Neurol Neurosurg Psychiatry. 2018;89(11):1191\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1826_CR36","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/brain\/awq171","volume":"133","author":"E Chabrol","year":"2010","unstructured":"Chabrol E, Navarro V, Provenzano G, Cohen I, Dinocourt C, Rivaud-P\u00e9choux S, et al. Electroclinical characterization of epileptic seizures in leucine-rich, glioma-inactivated 1-deficient mice. Brain. 2010;133(9):2749\u201362.","journal-title":"Brain"},{"issue":"6","key":"1826_CR37","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/brain\/awaa104","volume":"143","author":"M Ramberger","year":"2020","unstructured":"Ramberger M, Berretta A, Tan JMM, Sun B, Michael S, Yeo T, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020;143(6):1731\u201345.","journal-title":"Brain"},{"issue":"3","key":"1826_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ana.25666","volume":"87","author":"HC Kornau","year":"2020","unstructured":"Kornau HC, Kreye J, Stumpf A, Fukata Y, Parthier D, Sammons RP, et al. Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann Neurol. 2020;87(3):405\u201318.","journal-title":"Ann Neurol"},{"key":"1826_CR39","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.pneurobio.2022.102262","volume":"213","author":"P Baudin","year":"2022","unstructured":"Baudin P, Whitmarsh S, Cousyn L, Roussel D, Lecas S, Lehongre K, et al. Kv1.1 channels inhibition in the rat motor cortex recapitulates seizures associated with anti-LGI1 encephalitis. Prog Neurobiol. 2022;213:102262.","journal-title":"Prog Neurobiol"},{"issue":"11","key":"1826_CR40","first-page":"3144","volume":"141","author":"M Petit-Pedrol","year":"2018","unstructured":"Petit-Pedrol M, Sell J, Planagum\u00e0 J, Mannara F, Radosevic M, Haselmann H, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain. 2018;141(11):3144\u201359.","journal-title":"Brain"},{"issue":"3","key":"1826_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ana.24293","volume":"77","author":"X Peng","year":"2015","unstructured":"Peng X, Hughes EG, Moscato EH, Parsons TD, Dalmau J, Balice-Gordon RJ. Cellular plasticity induced by anti-\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol. 2015;77(3):381\u201398.","journal-title":"Ann Neurol"},{"issue":"24","key":"1826_CR42","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1523\/JNEUROSCI.4415-13.2014","volume":"34","author":"T Ohkawa","year":"2014","unstructured":"Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T, Sobue G, et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci. 2014;34(24):8151\u201363.","journal-title":"J Neurosci"},{"issue":"11","key":"1826_CR43","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","volume":"88","author":"M Spatola","year":"2017","unstructured":"Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI, et al. Investigations in GABA(A) receptor antibody-associated encephalitis. Neurology. 2017;88(11):1012\u201320.","journal-title":"Neurology"},{"issue":"14","key":"1826_CR44","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.cell.2022.06.025","volume":"185","author":"CM Noviello","year":"2022","unstructured":"Noviello CM, Kreye J, Teng J, Pr\u00fcss H, Hibbs RE. Structural mechanisms of GABA(A) receptor autoimmune encephalitis. Cell. 2022;185(14):2469-77.e13.","journal-title":"Cell"},{"issue":"1","key":"1826_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molmed.2022.09.011","volume":"29","author":"Sophie L. Duong","year":"2023","unstructured":"Duong SL, Pr\u00fcss H. Molecular disease mechanisms of human antineuronal monoclonal autoantibodies. Trends Mol Med. 2023; 29(1): 20-34.","journal-title":"Trends in Molecular Medicine"},{"issue":"3","key":"1826_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/epi4.12067","volume":"2","author":"A Nibber","year":"2017","unstructured":"Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, et al. Pathogenic potential of antibodies to the GABA(B) receptor. Epilepsia Open. 2017;2(3):355\u20139.","journal-title":"Epilepsia Open."},{"issue":"2","key":"1826_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/1531-8249(199908)46:2<263::AID-ANA19>3.0.CO;2-0","volume":"46","author":"K Ishida","year":"1999","unstructured":"Ishida K, Mitoma H, Song SY, Uchihara T, Inaba A, Eguchi S, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol. 1999;46(2):263\u20137.","journal-title":"Ann Neurol"},{"issue":"9","key":"1826_CR48","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/j.1528-1167.2010.02644.x","volume":"51","author":"CJ Stagg","year":"2010","unstructured":"Stagg CJ, Lang B, Best JG, McKnight K, Cavey A, Johansen-Berg H, et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia. 2010;51(9):1898\u2013901.","journal-title":"Epilepsia"},{"issue":"4","key":"1826_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.21917","volume":"67","author":"MP Malter","year":"2010","unstructured":"Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470\u20138.","journal-title":"Ann Neurol"},{"issue":"341","key":"1826_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577189","volume":"15","author":"X Li","year":"2020","unstructured":"Li X, Guo Q, Zheng Z, Wang X, Liu S. Immune-mediated epilepsy with GAD65 antibodies. J Neuroimmunol. 2020;15(341): 577189.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"1826_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.180.2.595","volume":"180","author":"J Kim","year":"1994","unstructured":"Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med. 1994;180(2):595\u2013606.","journal-title":"J Exp Med"},{"issue":"2","key":"1826_CR52","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4049\/jimmunol.156.2.818","volume":"156","author":"K Daw","year":"1996","unstructured":"Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol. 1996;156(2):818\u201325.","journal-title":"J Immunol"},{"issue":"18","key":"1826_CR53","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1212\/WNL.0b013e3182a9f531","volume":"81","author":"F Leypoldt","year":"2013","unstructured":"Leypoldt F, Titulaer MJ, Aguilar E, Walther J, B\u00f6nstrup M, Havemeister S, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology. 2013;81(18):1637\u20139.","journal-title":"Neurology"},{"issue":"3","key":"1826_CR54","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaneurol.2013.4580","volume":"71","author":"A DeSena","year":"2014","unstructured":"DeSena A, Graves D, Warnack W, Greenberg BM. Herpes simplex encephalitis as a potential cause of anti\u2013N-methyl-d-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol. 2014;71(3):344\u20136.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1826_CR55","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","volume":"17","author":"T Armangue","year":"2018","unstructured":"Armangue T, Spatola M, Vlagea A, Mattozzi S, C\u00e1rceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760\u201372.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1826_CR56","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/dmcn.13448","volume":"59","author":"M Nosadini","year":"2017","unstructured":"Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, et al. Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol. 2017;59(8):796\u2013805.","journal-title":"Dev Med Child Neurol"},{"key":"1826_CR57","doi-asserted-by":"crossref","unstructured":"Alexopoulos H, Kouremenos E, Akrivou S, Naoumis D, Antonopoulou M, Vlachoyiannopoulos P, et al. Post-Herpes Simplex Virus (HSV) Autoimmune Encephalitis: A Case Series and Novel Immunological Findings (P1.292). Neurology. 2016;86(16 Supplement):P1.292.","DOI":"10.1212\/WNL.86.16_supplement.P1.292"},{"key":"1826_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcv.2016.08.292","volume":"83","author":"N Sol\u00eds","year":"2016","unstructured":"Sol\u00eds N, Salazar L, Hasbun R. Anti-NMDA receptor antibody encephalitis with concomitant detection of Varicella zoster virus. J Clin Virol. 2016;83:26\u20138.","journal-title":"J Clin Virol"},{"issue":"24","key":"1826_CR59","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1212\/WNL.0000000000001072","volume":"83","author":"W-R Sch\u00e4bitz","year":"2014","unstructured":"Sch\u00e4bitz W-R, Rogalewski A, Hagemeister C, Bien CG. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology. 2014;83(24):2309\u201311.","journal-title":"Neurology"},{"issue":"20","key":"1826_CR60","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015726","volume":"98","author":"R Hou","year":"2019","unstructured":"Hou R, Wu J, He D, Yan Y, Li L. Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients: three case reports. Med (Baltim). 2019;98(20): e15726.","journal-title":"Med (Baltim)"},{"key":"1826_CR61","doi-asserted-by":"crossref","unstructured":"Valencia Sanchez C, Theel E, Binnicker M, Toledano M, McKeon A. Autoimmune encephalitis after SARS-CoV-2 infection. Case frequency, findings, and outcomes. Neurology 2021;97(23):e2262-e8.","DOI":"10.1212\/WNL.0000000000012931"},{"key":"1826_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2020.05.005","volume":"79","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya AA. Seizures associated with coronavirus infections. Seizure. 2020;79:49\u201352.","journal-title":"Seizure."},{"key":"1826_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.seizure.2021.05.003","volume":"89","author":"E Carroll","year":"2021","unstructured":"Carroll E, Melmed KR, Frontera J, Placantonakis DG, Galetta S, Balcer L, et al. Cerebrospinal fluid findings in patients with seizure in the setting of COVID-19: a review of the literature. Seizure. 2021;89:99\u2013106.","journal-title":"Seizure."},{"issue":"2","key":"1826_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.24858","volume":"81","author":"A van Sonderen","year":"2017","unstructured":"van Sonderen A, Roelen DL, Stoop JA, Verdijk RM, Haasnoot GW, Thijs RD, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol. 2017;81(2):193\u20138.","journal-title":"Ann Neurol"},{"issue":"4","key":"1826_CR65","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ana.25216","volume":"83","author":"SH Mueller","year":"2018","unstructured":"Mueller SH, F\u00e4rber A, Pr\u00fcss H, Melzer N, Golombeck KS, K\u00fcmpfel T, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol. 2018;83(4):863\u20139.","journal-title":"Ann Neurol"},{"key":"1826_CR66","doi-asserted-by":"publisher","unstructured":"Strippel C, Herrera-Rivero M, Wendorff M, Tietz AK, Degenhardt F, Witten A, et al. A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain. 2022; Mar 28:awac119.https:\/\/doi.org\/10.1093\/brain\/awac119. Online ahead of print. PMID: 35348614","DOI":"10.1093\/brain\/awac119"},{"issue":"8","key":"1826_CR67","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/brain\/awy109","volume":"141","author":"S Binks","year":"2018","unstructured":"Binks S, Varley J, Lee W, Makuch M, Elliott K, Gelfand JM, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018;141(8):2263\u201371.","journal-title":"Brain"},{"issue":"2","key":"1826_CR68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.24860","volume":"81","author":"TJ Kim","year":"2017","unstructured":"Kim TJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol. 2017;81(2):183\u201392.","journal-title":"Ann Neurol"},{"key":"1826_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcdb.2014.10.003","volume":"38","author":"EA van Vliet","year":"2015","unstructured":"van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol. 2015;38:26\u201334.","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"1826_CR70","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840\u201351.","journal-title":"N Engl J Med"},{"key":"1826_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.seizure.2016.08.003","volume":"41","author":"Z Lin","year":"2016","unstructured":"Lin Z, Si Q, Xiaoyi Z. Association between epilepsy and systemic autoimmune diseases: a meta-analysis. Seizure. 2016;41:160\u20136.","journal-title":"Seizure."},{"issue":"5","key":"1826_CR72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jamaneurol.2014.188","volume":"71","author":"MS Ong","year":"2014","unstructured":"Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014;71(5):569\u201374.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1826_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","volume":"7","author":"A Vezzani","year":"2011","unstructured":"Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31\u201340.","journal-title":"Nat Rev Neurol"},{"key":"1826_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","volume":"96","author":"A Vezzani","year":"2015","unstructured":"Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015;96:70\u201382.","journal-title":"Neuropharmacology"},{"issue":"8","key":"1826_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","volume":"15","author":"A Vezzani","year":"2019","unstructured":"Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15(8):459\u201372.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"1826_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3345\/kjp.2013.56.7.271","volume":"56","author":"Y Youn","year":"2013","unstructured":"Youn Y, Sung IK, Lee IG. The role of cytokines in seizures: interleukin (IL)-1\u03b2, IL-1Ra, IL-8, and IL-10. Korean J Pediatr. 2013;56(7):271\u20134.","journal-title":"Korean J Pediatr"},{"issue":"6","key":"1826_CR77","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s11064-011-0456-8","volume":"36","author":"C Zhou","year":"2011","unstructured":"Zhou C, Qi C, Zhao J, Wang F, Zhang W, Li C, et al. Interleukin-1\u03b2 inhibits voltage-gated sodium currents in a time- and dose-dependent manner in cortical neurons. Neurochem Res. 2011;36(6):1116\u201323.","journal-title":"Neurochem Res"},{"issue":"1","key":"1826_CR78","doi-asserted-by":"publisher","first-page":"17956","DOI":"10.1038\/s41598-022-22806-9","volume":"12","author":"G Ruffolo","year":"2022","unstructured":"Ruffolo G, Alfano V, Romagnolo A, Zimmer T, Mills JD, Cifelli P, et al. GABA(A) receptor function is enhanced by Interleukin-10 in human epileptogenic gangliogliomas and its effect is counteracted by Interleukin-1\u03b2. Sci Rep. 2022;12(1):17956.","journal-title":"Sci Rep"},{"issue":"7","key":"1826_CR79","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/89490","volume":"4","author":"P Bezzi","year":"2001","unstructured":"Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci. 2001;4(7):702\u201310.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1826_CR80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/epi.13950","volume":"59","author":"G Terrone","year":"2018","unstructured":"Terrone G, Pauletti A, Salamone A, Rizzi M, Villa BR, Porcu L, et al. Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. Epilepsia. 2018;59(1):79\u201391.","journal-title":"Epilepsia"},{"issue":"2","key":"1826_CR81","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ni.1831","volume":"11","author":"R Zhou","year":"2010","unstructured":"Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136\u201340.","journal-title":"Nat Immunol"},{"issue":"2","key":"1826_CR82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1515\/hsz-2013-0241","volume":"395","author":"J Lugrin","year":"2014","unstructured":"Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203\u201330.","journal-title":"Biol Chem"},{"issue":"2","key":"1826_CR83","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5698\/1535-7597-13.2.62","volume":"13","author":"O Devinsky","year":"2013","unstructured":"Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr. 2013;13(2):62\u20138.","journal-title":"Epilepsy Curr."},{"issue":"5","key":"1826_CR84","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.23648","volume":"72","author":"R Daneman","year":"2012","unstructured":"Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72(5):648\u201372.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"1826_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03472.x","volume":"53","author":"D Janigro","year":"2012","unstructured":"Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia. 2012;53(Suppl 1):26\u201334.","journal-title":"Epilepsia"},{"issue":"8","key":"1826_CR86","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/epi.12713","volume":"55","author":"S Salar","year":"2014","unstructured":"Salar S, Maslarova A, Lippmann K, Nichtweiss J, Weissberg I, Sheintuch L, et al. Blood-brain barrier dysfunction can contribute to pharmacoresistance of seizures. Epilepsia. 2014;55(8):1255\u201363.","journal-title":"Epilepsia"},{"issue":"6","key":"1826_CR87","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/brain\/awx073","volume":"140","author":"G Bar-Klein","year":"2017","unstructured":"Bar-Klein G, Lublinsky S, Kamintsky L, Noyman I, Veksler R, Dalipaj H, et al. Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis. Brain. 2017;140(6):1692\u2013705.","journal-title":"Brain"},{"key":"1826_CR88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.02.029","volume":"78","author":"I Weissberg","year":"2015","unstructured":"Weissberg I, Wood L, Kamintsky L, Vazquez O, Milikovsky DZ, Alexander A, et al. Albumin induces excitatory synaptogenesis through astrocytic TGF-\u03b2\/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction. Neurobiol Dis. 2015;78:115\u201325.","journal-title":"Neurobiol Dis"},{"key":"1826_CR89","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijms21020591","volume":"21","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W, Friedman A. Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both? Int J Mol Sci. 2020;21:2.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1826_CR90","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/j.1528-1167.2012.03666.x","volume":"53","author":"F Frigerio","year":"2012","unstructured":"Frigerio F, Frasca A, Weissberg I, Parrella S, Friedman A, Vezzani A, et al. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia. 2012;53(11):1887\u201397.","journal-title":"Epilepsia"},{"issue":"2","key":"1826_CR91","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","volume":"13","author":"S Varadkar","year":"2014","unstructured":"Varadkar S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, et al. Rasmussen\u2019s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2):195\u2013205.","journal-title":"Lancet Neurol"},{"issue":"5172","key":"1826_CR92","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.8036512","volume":"265","author":"SW Rogers","year":"1994","unstructured":"Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen\u2019s encephalitis. Science. 1994;265(5172):648\u201351.","journal-title":"Science"},{"issue":"1","key":"1826_CR93","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1212\/01.WNL.0000132651.66689.0F","volume":"63","author":"R Watson","year":"2004","unstructured":"Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology. 2004;63(1):43\u201350.","journal-title":"Neurology"},{"key":"1826_CR94","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.seizure.2020.07.023","volume":"81","author":"A Orsini","year":"2020","unstructured":"Orsini A, Foiadelli T, Carli N, Costagliola G, Masini B, Bonuccelli A, et al. Rasmussen\u2019s encephalitis: from immune pathogenesis towards targeted-therapy. Seizure. 2020;81:76\u201383.","journal-title":"Seizure."},{"issue":"1","key":"1826_CR95","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1186\/1742-2094-10-152","volume":"10","author":"V Ramaswamy","year":"2013","unstructured":"Ramaswamy V, Walsh JG, Sinclair DB, Johnson E, Tang-Wai R, Wheatley BM, et al. Inflammasome induction in Rasmussen\u2019s encephalitis: cortical and associated white matter pathogenesis. J Neuroinflamm. 2013;10(1):918.","journal-title":"J Neuroinflamm"},{"issue":"4","key":"1826_CR96","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-019-01958-5","volume":"137","author":"AR Tr\u00f6scher","year":"2019","unstructured":"Tr\u00f6scher AR, Wimmer I, Quemada-Garrido L, K\u00f6ck U, Gessl D, Verberk SGS, et al. Microglial nodules provide the environment for pathogenic T cells in human encephalitis. Acta Neuropathol. 2019;137(4):619\u201335.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1826_CR97","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/ane.13712","volume":"146","author":"C Tang","year":"2022","unstructured":"Tang C, Yang W, Luan G. Progress in pathogenesis and therapy of Rasmussen\u2019s encephalitis. Acta Neurol Scand. 2022;146(6):761\u20136.","journal-title":"Acta Neurol Scand"},{"issue":"179","key":"1826_CR98","volume":"18","author":"C Tang","year":"2021","unstructured":"Tang C, Wang X, Deng J, Xiong Z, Guan Y, Zhou J, et al. Increased inflammasome-activated pyroptosis mediated by caspase-1 in Rasmussen\u2019s encephalitis. Epilepsy Res. 2021;18(179): 106843.","journal-title":"Epilepsy Res"},{"key":"1826_CR99","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17457","author":"DF Leitner","year":"2022","unstructured":"Leitner DF, Lin Z, Sawaged Z, Kanshin E, Friedman D, Devore S, et al. Brain Molecular Mechanisms in Rasmussen Encephalitis. Epilepsia. 2022. https:\/\/doi.org\/10.1111\/epi.17457.","journal-title":"Epilepsia"},{"issue":"8","key":"1826_CR100","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/14737175.2016.1189328","volume":"16","author":"D Dubey","year":"2016","unstructured":"Dubey D, Blackburn K, Greenberg B, Stuve O, Vernino S. Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. Expert Rev Neurother. 2016;16(8):937\u201349.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"1826_CR101","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.mayocp.2021.02.019","volume":"96","author":"B Chen","year":"2021","unstructured":"Chen B, Lopez Chiriboga AS, Sirven JI, Feyissa AM. Autoimmune encephalitis-related seizures and epilepsy: diagnostic and therapeutic approaches. Mayo Clin Proc. 2021;96(8):2029\u201339.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1826_CR102","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ana.22307","volume":"69","author":"SR Irani","year":"2011","unstructured":"Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892\u2013900.","journal-title":"Ann Neurol"},{"issue":"6","key":"1826_CR103","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/jnnp-2018-318584","volume":"90","author":"JA Varley","year":"2019","unstructured":"Varley JA, Webb AJS, Balint B, Fung VSC, Sethi KD, Tijssen MAJ, et al. The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry. 2019;90(6):724\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1826_CR104","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","volume":"13","author":"M Petit-Pedrol","year":"2014","unstructured":"Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1826_CR105","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17925\/ENR.2013.08.01.31","volume":"8","author":"F Leypoldt","year":"2013","unstructured":"Leypoldt F, Wandinger KP, Bien CG, Dalmau J. Autoimmune encephalitis. Eur Neurol Rev. 2013;8(1):31\u20137.","journal-title":"Eur Neurol Rev."},{"key":"1826_CR106","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.seizure.2018.06.021","volume":"60","author":"C Steriade","year":"2018","unstructured":"Steriade C, Moosa ANV, Hantus S, Prayson RA, Alexopoulos A, Rae-Grant A. Electroclinical features of seizures associated with autoimmune encephalitis. Seizure. 2018;60:198\u2013204.","journal-title":"Seizure."},{"issue":"3","key":"1826_CR107","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00259-021-05507-9","volume":"49","author":"N De Leiris","year":"2022","unstructured":"De Leiris N, Ruel B, Vervandier J, Boucraut J, Grimaldi S, Horowitz T, et al. Decrease in the cortex\/striatum metabolic ratio on [(18)F]-FDG PET: a biomarker of autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2022;49(3):921\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1826_CR108","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166\u201377.","journal-title":"Ann Neurol"},{"issue":"3","key":"1826_CR109","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/epi.16820","volume":"62","author":"Y Li","year":"2021","unstructured":"Li Y, Tymchuk S, Barry J, Muppidi S, Le S. Antibody prevalence in epilepsy before surgery (APES) in drug-resistant focal epilepsy. Epilepsia. 2021;62(3):720\u20138.","journal-title":"Epilepsia"},{"issue":"3","key":"1826_CR110","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00415-020-10250-6","volume":"268","author":"A Rada","year":"2021","unstructured":"Rada A, Birnbacher R, Gobbi C, Kurthen M, Ludolph A, Naumann M, et al. Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. J Neurol. 2021;268(3):1059\u201369.","journal-title":"J Neurol"},{"key":"1826_CR111","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.seizure.2021.09.007","volume":"92","author":"SS Chen","year":"2021","unstructured":"Chen SS, Zhang YF, Di Q, Shi JP, Wang LL, Lin XJ, et al. Predictors and prognoses of epilepsy after anti-neuronal antibody-positive autoimmune encephalitis. Seizure. 2021;92:189\u201394.","journal-title":"Seizure."},{"issue":"2","key":"1826_CR112","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157\u201365.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1826_CR113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/CPJ.0000000000000219","volume":"6","author":"L Bartolini","year":"2016","unstructured":"Bartolini L. Practice current: how do you treat anti-NMDA receptor encephalitis? Neurol Clin Pract. 2016;6(1):69\u201372.","journal-title":"Neurol Clin Pract."},{"issue":"4","key":"1826_CR114","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00415-017-8407-1","volume":"264","author":"L Bartolini","year":"2017","unstructured":"Bartolini L, Muscal E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey. J Neurol. 2017;264(4):647\u201353.","journal-title":"J Neurol"},{"key":"1826_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673339","volume":"12","author":"E Sechi","year":"2021","unstructured":"Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Front Neurol. 2021;12: 673339.","journal-title":"Front Neurol"},{"key":"1826_CR116","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fimmu.2019.00324","volume":"10","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Tian X, Gu Y, Li F, Wang X. Application of plasma exchange in steroid-responsive encephalopathy. Front Immunol. 2019;10:324.","journal-title":"Front Immunol"},{"issue":"12","key":"1826_CR117","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00415-016-8277-y","volume":"263","author":"J Heine","year":"2016","unstructured":"Heine J, Ly LT, Lieker I, Slowinski T, Finke C, Pr\u00fcss H, et al. Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. J Neurol. 2016;263(12):2395\u2013402.","journal-title":"J Neurol"},{"issue":"2","key":"1826_CR118","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000207","volume":"3","author":"M Dogan Onugoren","year":"2016","unstructured":"Dogan Onugoren M, Golombeck KS, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M, et al. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm. 2016;3(2): e207.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1826_CR119","first-page":"9","volume":"22","author":"S Macher","year":"2018","unstructured":"Macher S, Zimprich F, De Simoni D, H\u00f6ftberger R, Rommer PS. Management of autoimmune encephalitis: an observational monocentric study of 38 patients. Front Immunol. 2018;22:9.","journal-title":"Front Immunol"},{"issue":"19","key":"1826_CR120","doi-asserted-by":"publisher","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","volume":"92","author":"MAAM de Bruijn","year":"2019","unstructured":"de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA<sub>B<\/sub>R encephalitis. Neurology. 2019;92(19):e2185\u201396.","journal-title":"Neurology"},{"issue":"8","key":"1826_CR121","first-page":"945","volume":"28","author":"L Cuttle","year":"2000","unstructured":"Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, et al. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos. 2000;28(8):945\u201350.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1826_CR122","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM197007022830103","volume":"283","author":"W Jubiz","year":"1970","unstructured":"Jubiz W, Meikle AW, Levinson RA, Mizutani S, West CD, Tyler FH. Effect of diphenylhydantoin on the metabolism of dexamethasone. N Engl J Med. 1970;283(1):11\u20134.","journal-title":"N Engl J Med"},{"issue":"2","key":"1826_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00003088-199018020-00004","volume":"18","author":"RL Nation","year":"1990","unstructured":"Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part II). Clin Pharmacokinet. 1990;18(2):131\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1826_CR124","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347\u201356.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1826_CR125","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00001813-199502000-00002","volume":"6","author":"PJ Koehler","year":"1995","unstructured":"Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs. 1995;6(1):19\u201333.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"1826_CR126","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/17425250903234709","volume":"5","author":"E Audet-Walsh","year":"2009","unstructured":"Audet-Walsh E, Auclair-Vincent S, Anderson A. Glucocorticoids and phenobarbital induce murine CYP2B genes by independent mechanisms. Expert Opin Drug Metab Toxicol. 2009;5(12):1501\u201311.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"1826_CR127","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","volume":"52","author":"X Wen","year":"2001","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52(5):547\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1826_CR128","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1826_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/epi.17147","volume":"63","author":"E Berman","year":"2022","unstructured":"Berman E, Noyman I, Medvedovsky M, Ekstein D, Eyal S. Not your usual drug-drug interactions: monoclonal antibody-based therapeutics may interact with antiseizure medications. Epilepsia. 2022;63(2):271\u201389.","journal-title":"Epilepsia"},{"issue":"6","key":"1826_CR130","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/neuonc\/nou030","volume":"16","author":"J Dalmau","year":"2014","unstructured":"Dalmau J, Rosenfeld MR. Autoimmune encephalitis update. Neuro Oncol. 2014;16(6):771\u20138.","journal-title":"Neuro Oncol"},{"issue":"10","key":"1826_CR131","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","volume":"77","author":"I Gabilondo","year":"2011","unstructured":"Gabilondo I, Saiz A, Gal\u00e1n L, Gonz\u00e1lez V, Jadraque R, Sabater L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996\u20139.","journal-title":"Neurology"},{"issue":"8","key":"1826_CR132","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco J, Irani SR, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897\u2013907.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1826_CR133","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10072-019-03930-3","volume":"40","author":"L Zuliani","year":"2019","unstructured":"Zuliani L, Nosadini M, Gastaldi M, Spatola M, Iorio R, Zoccarato M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019;40(10):2017\u201330.","journal-title":"Neurol Sci"},{"issue":"150","key":"1826_CR134","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20377","volume":"16","author":"J Stuby","year":"2020","unstructured":"Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020;16(150): w20377.","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"1826_CR135","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/epi.13797","volume":"58","author":"D Dubey","year":"2017","unstructured":"Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58(7):1181\u20139.","journal-title":"Epilepsia"},{"key":"1826_CR136","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","volume":"323","author":"D Dubey","year":"2018","unstructured":"Dubey D, Kothapalli N, McKeon A, Flanagan EP, Lennon VA, Klein CJ, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol. 2018;323:62\u201372.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1826_CR137","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1212\/WNL.0000000000006783","volume":"92","author":"R Balu","year":"2019","unstructured":"Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology. 2019;92(3):e244\u201352.","journal-title":"Neurology"},{"issue":"18","key":"1826_CR138","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","volume":"82","author":"M Toledano","year":"2014","unstructured":"Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AM, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578\u201386.","journal-title":"Neurology"},{"issue":"1","key":"1826_CR139","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/ane.12575","volume":"135","author":"B von Rhein","year":"2017","unstructured":"von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135(1):134\u201341.","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"1826_CR140","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1212\/01.WNL.0000099074.04539.E0","volume":"61","author":"T Granata","year":"2003","unstructured":"Granata T, Fusco L, Gobbi G, Freri E, Ragona F, Broggi G, et al. Experience with immunomodulatory treatments in Rasmussen\u2019s encephalitis. Neurology. 2003;61(12):1807\u201310.","journal-title":"Neurology"},{"issue":"1","key":"1826_CR141","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1212\/WNL.46.1.242","volume":"46","author":"PI Andrews","year":"1996","unstructured":"Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen\u2019s encephalitis. Neurology. 1996;46(1):242\u20136.","journal-title":"Neurology"},{"issue":"6","key":"1826_CR142","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp.69.6.711","volume":"69","author":"J Palace","year":"2000","unstructured":"Palace J, Lang B. Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry. 2000;69(6):711\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1826_CR143","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/epi.12042","volume":"54","author":"CG Bien","year":"2013","unstructured":"Bien CG, Tiemeier H, Sassen R, Kuczaty S, Urbach H, von Lehe M, et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia. 2013;54(3):543\u201350.","journal-title":"Epilepsia"},{"issue":"2","key":"1826_CR144","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1212\/WNL.0000000000011004","volume":"96","author":"S Pellegrin","year":"2021","unstructured":"Pellegrin S, Baldeweg T, Pujar S, D\u2019Arco F, Cantalupo G, Varadkar S, et al. Immunomodulation with azathioprine therapy in Rasmussen syndrome: a multimodal evaluation. Neurology. 2021;96(2):e267\u201379.","journal-title":"Neurology"},{"issue":"6","key":"1826_CR145","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/epi.13387","volume":"57","author":"S Lagarde","year":"2016","unstructured":"Lagarde S, Villeneuve N, Tr\u00e9buchon A, Kaphan E, Lepine A, McGonigal A, et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen\u2019s encephalitis: An open pilot study. Epilepsia. 2016;57(6):956\u201366.","journal-title":"Epilepsia"},{"issue":"2","key":"1826_CR146","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-0040-1708504","volume":"40","author":"KC Cay-Martinez","year":"2020","unstructured":"Cay-Martinez KC, Hickman RA, McKhann Ii GM, Provenzano FA, Sands TT. Rasmussen encephalitis: an update. Semin Neurol. 2020;40(2):201\u201310.","journal-title":"Semin Neurol"},{"issue":"1\u20132","key":"1826_CR147","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jneuroim.2013.09.017","volume":"265","author":"Y Hachiya","year":"2013","unstructured":"Hachiya Y, Uruha A, Kasai-Yoshida E, Shimoda K, Satoh-Shirai I, Kumada S, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol. 2013;265(1\u20132):128\u201330.","journal-title":"J Neuroimmunol"},{"key":"1826_CR148","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","volume":"4","author":"M Mah\u00e9vas","year":"2013","unstructured":"Mah\u00e9vas M, Michel M, Weill J-C, Reynaud C-A. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol. 2013;4:494.","journal-title":"Front Immunol"},{"issue":"6","key":"1826_CR149","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.27435","volume":"62","author":"A Khosroshahi","year":"2010","unstructured":"Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755\u201362.","journal-title":"Arthritis Rheum"},{"key":"1826_CR150","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G, Napodano C, Iorio R, Gulli F, et al. Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis. Front Immunol. 2020;11:613.","journal-title":"Front Immunol"},{"issue":"3","key":"1826_CR151","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1826_CR152","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2217\/imt-2017-0178","volume":"10","author":"KA Sacco","year":"2018","unstructured":"Sacco KA, Abraham RS. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;10(8):713\u201328.","journal-title":"Immunotherapy"},{"issue":"11","key":"1826_CR153","first-page":"CD013874","volume":"11","author":"G Filippini","year":"2021","unstructured":"Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev. 2021;11(11):CD013874.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1826_CR154","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83(1):13\u201326.","journal-title":"Ann Neurol"},{"issue":"1","key":"1826_CR155","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1756285615601933","volume":"9","author":"PS Sorensen","year":"2016","unstructured":"Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9(1):44\u201352.","journal-title":"Ther Adv Neurol Disord"},{"key":"1826_CR156","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40120-022-00327-x","volume":"11","author":"KM Blackburn","year":"2022","unstructured":"Blackburn KM, Denney DA, Hopkins SC, Vernino SA. Low recruitment in a double-blind, placebo-controlled trial of ocrelizumab for autoimmune encephalitis: a case series and review of lessons learned. Neurol Ther. 2022;11:893\u2013903.","journal-title":"Neurol Ther"},{"issue":"10206","key":"1826_CR157","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"key":"1826_CR158","unstructured":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04372615. Accessed 4 May 2021."},{"issue":"3","key":"1826_CR159","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"6","key":"1826_CR160","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/ene.15266","volume":"29","author":"F Scheibe","year":"2022","unstructured":"Scheibe F, Ostendorf L, Pr\u00fcss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847\u201354.","journal-title":"Eur J Neurol"},{"key":"1826_CR161","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2020","unstructured":"Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia Gravis. Front Immunol. 2020;10:3052.","journal-title":"Front Immunol"},{"issue":"3","key":"1826_CR162","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Spatola M, Schroeter CB, Wiendl H, L\u00fcnemann JD. Neonatal Fc receptor-targeted therapies in neurology. Neurotherapeutics. 2022;19(3):729\u201340.","journal-title":"Neurotherapeutics"},{"key":"1826_CR163","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9:414.","journal-title":"Sci Transl Med."},{"issue":"6","key":"1826_CR164","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia Gravis. A phase 2 randomized control trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"issue":"17","key":"1826_CR165","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","volume":"4","author":"T Robak","year":"2020","unstructured":"Robak T, Ka\u017amierczak M, Jarque I, Musteata V, Treli\u0144ski J, Cooper N, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020;4(17):4136\u201346.","journal-title":"Blood Adv"},{"key":"1826_CR166","unstructured":"SRL UB. A study to test the efficacy, safety, and pharmacokinetics of rozanolixizumab in adult study participants with leucine-rich glioma inactivated 1 autoimmune encephalitis. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04372615. Accessed 13 Apr 2022."},{"issue":"7","key":"1826_CR167","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1826_CR168","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748\u201355.","journal-title":"Nat Med"},{"issue":"7","key":"1826_CR169","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, K\u00fchl AA, Rubbert-Roth A, Lorenz HM, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1826_CR170","first-page":"CD010816","volume":"20","author":"K Scott","year":"2016","unstructured":"Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;20(4):CD010816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1826_CR171","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/acn3.557","volume":"5","author":"Y-W Shin","year":"2018","unstructured":"Shin Y-W, Lee S-T, Kim T-J, Jun J-S, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2018;5(5):598\u2013605.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"1826_CR172","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","volume":"88","author":"F Scheibe","year":"2017","unstructured":"Scheibe F, Pr\u00fcss H, Mengel AM, Kohler S, N\u00fcmann A, K\u00f6hnlein M, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366\u201370.","journal-title":"Neurology"},{"issue":"11","key":"1826_CR173","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/ene.13759","volume":"25","author":"S Keddie","year":"2018","unstructured":"Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M, et al. Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. Eur J Neurol. 2018;25(11):1384\u20138.","journal-title":"Eur J Neurol"},{"key":"1826_CR174","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fneur.2020.00188","volume":"11","author":"MT Turnbull","year":"2020","unstructured":"Turnbull MT, Siegel JL, Becker TL, Stephens AJ, Lopez-Chiriboga AS, Freeman WD. Early bortezomib therapy for refractory anti-NMDA receptor encephalitis. Front Neurol. 2020;11:188.","journal-title":"Front Neurol"},{"key":"1826_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577586","volume":"356","author":"A Dinoto","year":"2021","unstructured":"Dinoto A, Cheli M, Bratina A, Sartori A, Manganotti P. Bortezomib in anti-N-Methyl-d-aspartate-receptor (NMDA-R) encephalitis: a systematic review. J Neuroimmunol. 2021;356: 577586.","journal-title":"J Neuroimmunol"},{"key":"1826_CR176","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/B978-0-12-405546-9.00049-2","volume-title":"Stiehm's immune deficiencies","author":"R Eisenberg","year":"2014","unstructured":"Eisenberg R. Chapter 49\u2014immune compromise associated with biologics. In: Sullivan KE, Stiehm ER, editors. Stiehm\u2019s immune deficiencies. Amsterdam: Academic Press; 2014. p. 889\u2013906."},{"issue":"3","key":"1826_CR177","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JND-190464","volume":"7","author":"S Datta","year":"2020","unstructured":"Datta S, Singh S, Govindarajan R. Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: a case series. J Neuromusc Dis. 2020;7(3):269\u201377.","journal-title":"J Neuromusc Dis"},{"issue":"Suppl 15","key":"1826_CR178","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/WNL.94.15_supplement.1691","volume":"94","author":"S Singh","year":"2020","unstructured":"Singh S, Singh H, Datta S, Govindarajan R. Eculizumab in the treatment of seronegative refractory generalized myasthenia gravis. Neurology. 2020;94(Suppl 15):1691.","journal-title":"Neurology"},{"issue":"12","key":"1826_CR179","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"Pt 5","key":"1826_CR180","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/aws082","volume":"135","author":"CG Bien","year":"2012","unstructured":"Bien CG, Vincent A, Barnett MH, Becker AJ, Bl\u00fcmcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(Pt 5):1622\u201338.","journal-title":"Brain"},{"issue":"3","key":"1826_CR181","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s13311-021-01178-4","volume":"19","author":"I Smets","year":"2022","unstructured":"Smets I, Titulaer MJ. Antibody therapies in autoimmune encephalitis. Neurotherapeutics. 2022;19(3):823\u201331.","journal-title":"Neurotherapeutics"},{"issue":"368","key":"1826_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577867","volume":"15","author":"AJ Gill","year":"2022","unstructured":"Gill AJ, Venkatesan A. Pathogenic mechanisms in neuronal surface autoantibody-mediated encephalitis. J Neuroimmunol. 2022;15(368): 577867.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"1826_CR183","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspec Biol. 2014;6(10): a016295.","journal-title":"Cold Spring Harb Perspec Biol."},{"issue":"4","key":"1826_CR184","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","volume":"171","author":"G Cassese","year":"2003","unstructured":"Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171(4):1684\u201390.","journal-title":"J Immunol"},{"issue":"8","key":"1826_CR185","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/leu.2014.61","volume":"28","author":"M Jourdan","year":"2014","unstructured":"Jourdan M, Cren M, Robert N, Bollor\u00e9 K, Fest T, Duperray C, et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia. 2014;28(8):1647\u201356.","journal-title":"Leukemia"},{"issue":"4","key":"1826_CR186","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","volume":"13","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824\u201332.","journal-title":"Neurotherapeutics"},{"key":"1826_CR187","first-page":"5697670","volume":"2020","author":"M Benucci","year":"2020","unstructured":"Benucci M, Tramacere L, Infantino M, Manfredi M, Grossi V, Damiani A, et al. Efficacy of tocilizumab in limbic encephalitis with anti-CASPR2 antibodies. Case Rep Neurol Med. 2020;2020:5697670.","journal-title":"Case Rep Neurol Med"},{"issue":"8","key":"1826_CR188","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","volume":"70","author":"C Krogias","year":"2013","unstructured":"Krogias C, Hoepner R, M\u00fcller A, Schneider-Gold C, Schr\u00f6der A, Gold R. Successful treatment of anti-caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol. 2013;70(8):1056\u20139.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1826_CR189","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s13311-020-00921-7","volume":"18","author":"WJ Lee","year":"2021","unstructured":"Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in Anti-NMDAR encephalitis. Neurotherapeutics. 2021;18(1):474\u201387.","journal-title":"Neurotherapeutics"},{"key":"1826_CR190","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2018.07.016","volume":"86","author":"RL Randell","year":"2018","unstructured":"Randell RL, Adams AV, Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pediatric Neurol. 2018;86:66\u20138.","journal-title":"Pediatric Neurol"},{"issue":"8","key":"1826_CR191","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"1826_CR192","doi-asserted-by":"publisher","first-page":"11534","DOI":"10.1073\/pnas.190206797","volume":"97","author":"A Vezzani","year":"2000","unstructured":"Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA. 2000;97(21):11534\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1826_CR193","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.nbd.2013.07.015","volume":"59","author":"FM Noe","year":"2013","unstructured":"Noe FM, Polascheck N, Frigerio F, Bankstahl M, Ravizza T, Marchini S, et al. Pharmacological blockade of IL-1\u03b2\/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013;59:183\u201393.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1826_CR194","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1684\/epd.2021.1283","volume":"23","author":"CH Choi","year":"2021","unstructured":"Choi CH, Ma SH, Ma KK, Leung H, Mok VC. Super-refractory status epilepticus in autoimmune encephalitis treated with interleukin-1 receptor antagonist, anakinra. Epileptic Disord. 2021;23(3):500\u20135.","journal-title":"Epileptic Disord"},{"issue":"12","key":"1826_CR195","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/art.41436","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Quartier P, Alexeeva E, Constantin T, Kon\u00e9-Paut I, Marzan K, et al. Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis with and without fever at baseline: results from an open-label. Active-Treatment Extension Study. Arthritis Rheum. 2020;72(12):2147\u201358.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1826_CR196","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064\u201376.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1826_CR197","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1021\/acs.jmedchem.5b01091","volume":"59","author":"AG Baldwin","year":"2016","unstructured":"Baldwin AG, Brough D, Freeman S. Inhibiting the inflammasome: a chemical perspective. J Med Chem. 2016;59(5):1691\u2013710.","journal-title":"J Med Chem"},{"key":"1826_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100307","volume":"16","author":"EO Sj\u00f6str\u00f6m","year":"2021","unstructured":"Sj\u00f6str\u00f6m EO, Culot M, Leickt L, \u00c5strand M, Nordling E, Gosselet F, et al. Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier. Brain Behav Immun Health. 2021;16: 100307.","journal-title":"Brain Behav Immun Health."},{"issue":"1","key":"1826_CR199","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12974-018-1063-2","volume":"15","author":"AD DeSena","year":"2018","unstructured":"DeSena AD, Do T, Schulert GS. Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J Neuroinflamm. 2018;15(1):38.","journal-title":"J Neuroinflamm"},{"key":"1826_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.741244","volume":"13","author":"G Costagliola","year":"2022","unstructured":"Costagliola G, Depietri G, Michev A, Riva A, Foiadelli T, Savasta S, et al. Targeting inflammatory mediators in epilepsy: a systematic review of its molecular basis and clinical applications. Front Neurol. 2022;13: 741244.","journal-title":"Front Neurol"},{"issue":"6","key":"1826_CR201","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW van Oosten","year":"1996","unstructured":"van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531\u20134.","journal-title":"Neurology"},{"issue":"3\u20134","key":"1826_CR202","first-page":"361","volume":"76","author":"T Kondo","year":"2014","unstructured":"Kondo T, Fukuta M, Takemoto A, Takami Y, Sato M, Takahashi N, et al. Limbic encephalitis associated with relapsing polychondritis responded to infliximab and maintained its condition without recurrence after discontinuation: a case report and review of the literature. Nagoya J Med Sci. 2014;76(3\u20134):361\u20138.","journal-title":"Nagoya J Med Sci"},{"issue":"2","key":"1826_CR203","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s13760-014-0322-y","volume":"115","author":"N Fockaert","year":"2015","unstructured":"Fockaert N, Goffin K, Demaerel P, Van Paesschen W. Infliximab-associated autoimmune limbic encephalitis: a case report. Acta Neurol Belg. 2015;115(2):161\u20133.","journal-title":"Acta Neurol Belg"},{"key":"1826_CR204","doi-asserted-by":"crossref","unstructured":"Tofacitinib. Drugs R D. 2010;10(4):271\u201384.","DOI":"10.2165\/11588080-000000000-00000"},{"key":"1826_CR205","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/epi.16848","volume":"62","author":"Y Jang","year":"2021","unstructured":"Jang Y, Lee W-J, Lee H, Chu K, Lee S, Lee S-T. Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia. 2021;62:e53\u20139.","journal-title":"Epilepsia"},{"issue":"5","key":"1826_CR206","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"key":"1826_CR207","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2016.09.001","volume":"299","author":"J-A Lim","year":"2016","unstructured":"Lim J-A, Lee S-T, Moon J, Jun J-S, Park B-S, Byun J-I, et al. New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2. J Neuroimmunol. 2016;299:107\u201311.","journal-title":"J Neuroimmunol"},{"key":"1826_CR208","doi-asserted-by":"crossref","unstructured":"Close R, Bale P, Gallagher K, Ambegaonkar G, Rossor T, Abbassi N, et al. Poster 137\u2003Growing up on biologics: a case report of development of NMDAr encephalitis in a young person with JIA on abatacept. Rheumatology. 2020;59(Supplement_2):ii68.","DOI":"10.1093\/rheumatology\/keaa111.132"},{"issue":"2","key":"1826_CR209","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","volume":"321","author":"W Wannamaker","year":"2007","unstructured":"Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509\u201316.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1826_CR210","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13311-011-0039-z","volume":"8","author":"M Maroso","year":"2011","unstructured":"Maroso M, Balosso S, Ravizza T, Iori V, Wright CI, French J, et al. Interleukin-1\u03b2 biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011;8(2):304\u201315.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1826_CR211","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","volume":"103","author":"M Bialer","year":"2013","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103(1):2\u201330.","journal-title":"Epilepsy Res"},{"issue":"6","key":"1826_CR212","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/1074248417702890","volume":"22","author":"X-M Yang","year":"2017","unstructured":"Yang X-M, Downey JM, Cohen MV, Housley NA, Alvarez DF, Audia JP. The highly selective caspase-1 inhibitor VX-765 provides additive protection against myocardial infarction in rat hearts when combined with a platelet inhibitor. J Cardiovasc Pharmacol Ther. 2017;22(6):574\u20138.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1826_CR213","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.18632\/aging.203907","volume":"14","author":"H Li","year":"2022","unstructured":"Li H, Guo Z, Chen J, Du Z, Lu H, Wang Z, et al. Computational research of Belnacasan and new Caspase-1 inhibitor on cerebral ischemia reperfusion injury. Aging (Albany NY). 2022;14(4):1848\u201364.","journal-title":"Aging (Albany NY)."},{"issue":"1","key":"1826_CR214","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1038\/s41467-020-18405-9","volume":"11","author":"J Flores","year":"2020","unstructured":"Flores J, No\u00ebl A, Foveau B, Beauchet O, LeBlanc AC. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun. 2020;11(1):4571.","journal-title":"Nat Commun"},{"issue":"23","key":"1826_CR215","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, Brun MK, Sandanger \u00d8, Bj\u00f8rlykke KH, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384.","journal-title":"JAMA"},{"issue":"2","key":"1826_CR216","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1017\/S0317167100013676","volume":"40","author":"R Dhamija","year":"2013","unstructured":"Dhamija R, Eckert S, Wirrell E. Ketogenic diet. Can J Neurol Sci. 2013;40(2):158\u201367.","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"1826_CR217","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/j.1528-1167.2012.03592.x","volume":"53","author":"AW Pong","year":"2012","unstructured":"Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC. Glucose transporter type I deficiency syndrome: epilepsy phenotypes and outcomes. Epilepsia. 2012;53(9):1503\u201310.","journal-title":"Epilepsia"},{"key":"1826_CR218","doi-asserted-by":"crossref","unstructured":"Andrea-Meira I, Rom\u00e3o TT, Pires do Prado HJ, Kr\u00fcger LT, Pires MEP, da Concei\u00e7\u00e3o PO. Ketogenic Diet and Epilepsy: What We Know So Far. Front Neurosci 2019;13:5.","DOI":"10.3389\/fnins.2019.00005"},{"key":"1826_CR219","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/nu11102510","volume":"11","author":"M U\u0142amek-Kozio\u0142","year":"2019","unstructured":"U\u0142amek-Kozio\u0142 M, Czuczwar SJ, Januszewski S, Pluta R. Ketogenic diet and epilepsy. Nutrients. 2019;11:10.","journal-title":"Nutrients"},{"key":"1826_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106499","volume":"168","author":"L Rudy","year":"2020","unstructured":"Rudy L, Carmen R, Daniel R, Artemio R, Mois\u00e9s RO. Anticonvulsant mechanisms of the ketogenic diet and caloric restriction. Epilepsy Res. 2020;168: 106499.","journal-title":"Epilepsy Res"},{"key":"1826_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106444","volume":"167","author":"M Murugan","year":"2020","unstructured":"Murugan M, Boison D. Ketogenic diet, neuroprotection, and antiepileptogenesis. Epilepsy Res. 2020;167: 106444.","journal-title":"Epilepsy Res"},{"issue":"7","key":"1826_CR222","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2018.04.027","volume":"173","author":"CA Olson","year":"2018","unstructured":"Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018;173(7):1728-41.e13.","journal-title":"Cell"},{"key":"1826_CR223","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.eplepsyres.2018.09.013","volume":"147","author":"A Peng","year":"2018","unstructured":"Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu X, et al. Altered composition of the gut microbiome in patients with drug-resistant epilepsy. Epilepsy Res. 2018;147:102\u20137.","journal-title":"Epilepsy Res"},{"issue":"6","key":"1826_CR224","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3920\/BM2018.0018","volume":"9","author":"M G\u00f3mez-Egu\u00edlaz","year":"2018","unstructured":"G\u00f3mez-Egu\u00edlaz M, Ram\u00f3n-Trapero JL, P\u00e9rez-Mart\u00ednez L, Blanco JR. The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study. Benef Microbes. 2018;9(6):875\u201381.","journal-title":"Benef Microbes."},{"key":"1826_CR225","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.12.010","volume":"129","author":"M Carre\u00f1o","year":"2017","unstructured":"Carre\u00f1o M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101\u20135.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1826_CR226","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10309-020-00355-3","volume":"33","author":"S R\u00fcegg","year":"2020","unstructured":"R\u00fcegg S. EEG bei Autoimmunenzephalitiden. Zeitschr Epileptol. 2020;33(4):278\u201387.","journal-title":"Zeitschr Epileptol"},{"issue":"1","key":"1826_CR227","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1212\/WNL.44.1.140","volume":"44","author":"WC Jean","year":"1994","unstructured":"Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology. 1994;44(1):140\u20137.","journal-title":"Neurology"},{"issue":"4","key":"1826_CR228","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1468-1331.2002.00416.x","volume":"9","author":"F Blaes","year":"2002","unstructured":"Blaes F, Klotz M, Funke D, Strittmatter M, Kraus J, Kaps M. Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes. Eur J Neurol. 2002;9(4):369\u201372.","journal-title":"Eur J Neurol"},{"issue":"6","key":"1826_CR229","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","volume":"13","author":"L Sabater","year":"2014","unstructured":"Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1826_CR230","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","volume":"13","author":"L Sabater","year":"2016","unstructured":"Sabater L, Planagum\u00e0 J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflamm. 2016;13(1):226.","journal-title":"J Neuroinflamm"},{"issue":"8","key":"1826_CR231","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.clinph.2014.01.001","volume":"125","author":"FP da Silva-J\u00fanior","year":"2014","unstructured":"da Silva-J\u00fanior FP, Castro LH, Andrade JQ, Bastos CG, Moreira CH, Val\u00e9rio RM, et al. Serial and prolonged EEG monitoring in anti-N-Methyl-d-Aspartate receptor encephalitis. Clin Neurophysiol. 2014;125(8):1541\u20134.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"1826_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2011.11.029","volume":"24","author":"PW Kaplan","year":"2012","unstructured":"Kaplan PW, Rossetti AO, Kaplan EH, Wieser HG. Proposition: limbic encephalitis may represent limbic status epilepticus. A review of clinical and EEG characteristics. Epilepsy Behav. 2012;24(1):1\u20136.","journal-title":"Epilepsy Behav"},{"issue":"11","key":"1826_CR233","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","volume":"79","author":"SE Schmitt","year":"2012","unstructured":"Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094\u2013100.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1826_CR234","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2015.04.009","volume":"353","author":"J Wang","year":"2015","unstructured":"Wang J, Wang K, Wu D, Liang H, Zheng X, Luo B. Extreme delta brush guides to the diagnosis of anti-NMDAR encephalitis. J Neurol Sci. 2015;353(1\u20132):81\u20133.","journal-title":"J Neurol Sci"},{"issue":"7","key":"1826_CR235","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinph.2017.04.015","volume":"128","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu G, Jiang MD, Li LP, Su YY. Analysis of electroencephalogram characteristics of anti-NMDA receptor encephalitis patients in China. Clin Neurophysiol. 2017;128(7):1227\u201333.","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"1826_CR236","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1684\/epd.2017.0942","volume":"19","author":"J Ueda","year":"2017","unstructured":"Ueda J, Kawamoto M, Hikiami R, Ishii J, Yoshimura H, Matsumoto R, et al. Serial EEG findings in anti-NMDA receptor encephalitis: correlation between clinical course and EEG. Epileptic Disord. 2017;19(4):465\u201370.","journal-title":"Epileptic Disord"},{"issue":"1","key":"1826_CR237","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1550059419868919","volume":"51","author":"N Lin","year":"2020","unstructured":"Lin N, Huang Y, Jin L, Lu Q, Liu Q, Zhou X, et al. Electroencephalogram and clinical characteristics and correlations in patients with anti-N-Methyl-d-aspartate receptor encephalitis. Clin EEG Neurosci. 2020;51(1):51\u201360.","journal-title":"Clin EEG Neurosci"},{"issue":"10","key":"1826_CR238","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.clinph.2018.02.130","volume":"129","author":"C Steriade","year":"2018","unstructured":"Steriade C, Hantus S, Moosa ANV, Rae-Grant AD. Extreme delta\u2014with or without brushes: a potential surrogate marker of disease activity in anti-NMDA-receptor encephalitis. Clin Neurophysiol. 2018;129(10):2197\u2013204.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"1826_CR239","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neucli.2015.12.009","volume":"46","author":"E Chanson","year":"2016","unstructured":"Chanson E, Bicilli \u00c9, Lauxerois M, Kauffmann S, Chabanne R, Ducray F, et al. Anti-NMDA-R encephalitis: should we consider extreme delta brush as electrical status epilepticus? Neurophysiol Clin. 2016;46(1):17\u201325.","journal-title":"Neurophysiol Clin"},{"issue":"1","key":"1826_CR240","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1550059416642660","volume":"48","author":"EP Foff","year":"2017","unstructured":"Foff EP, Taplinger D, Suski J, Lopes MB, Quigg M. EEG findings may serve as a potential biomarker for anti-NMDA receptor encephalitis. Clin EEG Neurosci. 2017;48(1):48\u201353.","journal-title":"Clin EEG Neurosci"},{"issue":"2","key":"1826_CR241","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clinph.2018.10.017","volume":"130","author":"S Jeannin-Mayer","year":"2019","unstructured":"Jeannin-Mayer S, Andr\u00e9-Obadia N, Rosenberg S, Boutet C, Honnorat J, Antoine JC, et al. EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns. Clin Neurophysiol. 2019;130(2):289\u201396.","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"1826_CR242","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1550059417745185","volume":"49","author":"A Miao","year":"2018","unstructured":"Miao A, Wang X. Ictal rhythmic alpha sinusoidal waves in 3 cases of anti-NMDAR encephalitis. Clin EEG Neurosci. 2018;49(5):302\u20135.","journal-title":"Clin EEG Neurosci"},{"key":"1826_CR243","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.yebeh.2018.04.007","volume":"84","author":"C Limotai","year":"2018","unstructured":"Limotai C, Denlertchaikul C, Saraya AW, Jirasakuldej S. Predictive values and specificity of electroencephalographic findings in autoimmune encephalitis diagnosis. Epilepsy Behav. 2018;84:29\u201336.","journal-title":"Epilepsy Behav"},{"key":"1826_CR244","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2018.12.015","volume":"65","author":"L Gillinder","year":"2019","unstructured":"Gillinder L, Warren N, Hartel G, Dionisio S, O\u2019Gorman C. EEG findings in NMDA encephalitis\u2014a systematic review. Seizure. 2019;65:20\u20134.","journal-title":"Seizure."},{"key":"1826_CR245","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jocn.2019.07.049","volume":"68","author":"L Yao","year":"2019","unstructured":"Yao L, Yue W, Xunyi W, Jianhong W, Guoxing Z, Zhen H. Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis: a follow-up study in East China. J Clin Neurosci. 2019;68:73\u20139.","journal-title":"J Clin Neurosci"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01826-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01826-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01826-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T20:52:24Z","timestamp":1728766344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01826-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":245,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01826-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"7 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by University of Basel. This review was funded by the Swiss Academy of Medical Sciences (YTCR 11\/21; to J.F), the Swiss National Science Foundation (PCEFP3_194609), the National Multiple Sclerosis Society (FG-1708-28871), the Goldschmidt Jacobson Foundation, the Gottfried and Julia Bangerter-Rhyner Foundation, the Propatient Foundation, the Fondation Pierre Mercier pour la Science, and the University of Basel (all to A.-K.P.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A-K.P. has received speaker honoraria, research support or research\/travel support from Roche and Biogen all used for research and without influence on the manuscript. S.R. has received funding from the Swiss National Science Foundation (grant number 320030_169379\/1 and co-applicant for grant numbers 33CM30_125115\/1 and 33CM30_140338\/1, and from UCB-pharma. He has received honoraria from serving on the scientific advisory boards of Arvelle\/Angelini, Bial, Eisai, GW, and UCB-pharma, and from serving as a consultant for Arvelle\/Angelini, Eisai, Jazz Pharmaceuticals, Pfizer, Novartis, Sandoz, and UCB-pharma. He has received speaker\u2019s honoraria from Eisai and Novartis. He does not hold any stocks of any pharmaceutical industries or manufacturers of medical devices. He disclosed that he is the past-president of the Swiss League against Epilepsy (no payments), Editor-in-chief of Zeitschrift f\u00fcr Epileptologie\/ Clinical Epileptology (from 2023) (no payments). J.F., T.N. declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A-K.P. and S.R. designed the review and supervised the work. J. F., T.N. and S.R. did the initial literature search. A-K.P., J.F. and T.N. drew the figures and composed the tables. All authors drafted and critically revised the manuscript, read and approved the final submitted paper and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}